Patents by Inventor Mayumi SUE

Mayumi SUE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-SIRPa ANTIBODY
    Publication number: 20240294660
    Abstract: An anti-SIRP? antibody that can be used as a tumor agent and an anti-tumor agent comprising the antibody as an active ingredient. An antibody that binds specifically to human SIRP? to inhibit binding of human SIRP? to CD47.
    Type: Application
    Filed: May 10, 2024
    Publication date: September 5, 2024
    Applicants: National University Corporation Kobe University, Daiichi Sankyo Company, Limited
    Inventors: Takashi Matozaki, Mayumi Sue, Kensuke Nakamura, Chigusa Yoshimura
  • Anti-SIRPalpha antibody
    Patent number: 12024566
    Abstract: An anti-SIRP? antibody that can be used as a tumor agent and an anti-tumor agent comprising the antibody as an active ingredient. An antibody that binds specifically to human SIRP? to inhibit binding of human SIRP? to CD47.
    Type: Grant
    Filed: July 9, 2019
    Date of Patent: July 2, 2024
    Assignees: NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Takashi Matozaki, Mayumi Sue, Kensuke Nakamura, Chigusa Yoshimura
  • COMBINATION OF ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPalpha ANTIBODY
    Publication number: 20230414778
    Abstract: A pharmaceutical composition and a method of treatment having excellent antitumor effect and safety are provided. A pharmaceutical composition and a method of treatment wherein an antibody-drug conjugate, in which a drug-linker and an antibody are bound by a thioether bond represented by the following formula (A represents the binding position with an antibody), and a SIRP?-CD47 interaction inhibitor, such as an anti-SIRP? antibody, are administrated in combination. Alternatively, a pharmaceutical composition and a method of treatment wherein said antibody-drug conjugate and SIRP?-CD47 interaction inhibitor, such as an anti-SIRP? antibody, are administrated in combination and are used for the treatment of a disease improved by an action of activating antitumor immunity.
    Type: Application
    Filed: November 10, 2021
    Publication date: December 28, 2023
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Mayumi SUE, Takuya TSUBAKI, Yoko ISHIMOTO
  • ANTI-SIRPalpha ANTIBODY
    Publication number: 20210155707
    Abstract: An anti-SIRP? antibody that can be used as a tumor agent and an anti-tumor agent comprising the antibody as an active ingredient. An antibody that binds specifically to human SIRP? to inhibit binding of human SIRP? to CD47.
    Type: Application
    Filed: July 9, 2019
    Publication date: May 27, 2021
    Applicants: NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Takashi MATOZAKI, Mayumi SUE, Kensuke NAKAMURA, Chigusa YOSHIMURA